- Home
- News
- canada saskatchewan
- biomedical development
Refine by
Biomedical Development Articles & Analysis
51 news found
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
Lumen Bioscience — a clinical stage biopharmaceutical company developing biologic drugs for highly prevalent diseases — announced today preliminary results from a Biomedical Advanced Research and Development Authority (BARDA)-supported effort to develop an intranasal formulation of its drug candidate, LMN-301. This drug, produced in spirulina, contains an antibody cocktail for ...
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project ...
The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics ...
Celdara Medical, LLC today announced that the National Institute of Aging’s Research and Entrepreneurial Development Immersion (REDI) initiative has awarded an R25 Entrepreneurship Enhancement Award to fund the company’s comprehensive training program focused on Alzheimer’s Disease: the Alzheimer’s-focused Celdara Medical High-Potential Entrepreneurs’ Fellowship ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Funding from the grant will be used to further the development of ENA001, Enalare's ...
Proceeds will support product development and expansion of in-house cGMP manufacturing capabilities Company anticipates initiating Phase 2 trial of CRISPR-Cas3-enhanced bacteriophage precision medicine for UTIs mid-2022 Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse ...
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKO Dr. Gary Nabel, ModeX President and CEO, former Chief Scientific Officer at Sanofi and founder of NIH’s Vaccine Research Center, joins OPKO as Chief Innovation Officer and a member of OPKO’s Board of Directors Alexis Borisy, ModeX Lead ...
Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced its support and recognition of the DEA’s National Prescription Drug Take Back Day on April 30, 2022. As stated in the DEA’s release, the drug overdose ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for REGEN-COV (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure ...
Affinity Biosensors Ultra-Rapid Phenotypical AST by Microbe Mass Measurement has been selected as a Step 1 semifinalist in the Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge by the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR). The ...
Visby Medical™, a leading medical diagnostic company, today announced that it has received an additional $25.5M in federal funding to develop and validate an at-home combination Flu-Covid test from the Biomedical Advanced Research and Development Authority (BARDA).The developmental-stage Flu-COVID PCR Test is a single-use, handheld, all-in-one PCR device that detects and distinguishes ...
Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® FLEX SP EXTREMITIES, Synthetic Bioactive Bone Graft. Using Synergy’s proprietary BIOSPHERE® Technology, BIOSPHERE® FLEX SP Extremities is a sheet putty composed of innovative spherical bioactive glass granules combined with a porous collagen/sodium hyaluronate ...
LightDeck Diagnostics, the company leveraging planar waveguide technology to deliver lab-quality diagnostics in minutes, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2022. This year’s list honors businesses that are making the biggest impact on their industries and culture as a whole—ultimately thriving in ...
Berkshire Biomedical Corporation (“Berkshire” or “the Company”) is focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness. The Company announced today that its lead product, the Computerized Oral Prescription Administration System (COPA™), has been honored as a 2022 Top Texas Tech Startup in the ...
Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System. Synergy continues to add solutions for surgeons with new innovative biomaterial products to an already successful portfolio. Leveraging off the proven success of the first-generation design, BIOSPHERE® ...
Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics announced today the appointment of W. Allan Alexander, MD as the company’s Chief Medical Officer, effective immediately. “Allan joining the team is an important milestone for Cellphire,” said Mike Gaffney, Chief Executive Officer. “His deep ...
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial launch. This latest contract action, ...